Cleveland BioLabs sinks on BARDA snub of radiation drug
This article was originally published in Scrip
Executive Summary
Cleveland BioLabs (CBLI) had some “splainin to do” on 4 April when confronted by analysts and investors seeking answers about why the US Biomedical Advanced Research and Development Authority (BARDA) refused to fund the later development of the firm's investigational acute radiation syndrome agent CBLB502 as a medical countermeasure.